Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation

Panagiotis A. Konstantinopoulos, Jae Weon Kim, Gilles Freyer, Jung Yun Lee, Lydia Gaba, Rachel N. Grisham, Nicoletta Colombo, Xiaohua Wu, Jalid Sehouli, Felipe Cruz, David Cibula, Bradley J. Monk, Gitte-Bettina Nyvang, Michael Friedlander, Domenica Lorusso, Els Van Nieuwenhuysen, Rozita Malik, Rosalind Glasspool, Christian Marth, Alexandra Leary, Alfonso Cortés-Salgado, Claudio Zamagni, Frederik Marmé, Jozef Sufliarsky, Patsy Hinson, Monica Zuradelli, Craig Wang, Fei Su, Ines Paule, Michelle Miller, Ursula A. Matulonis, Antonio González-Martín

Open source

DOI: 10.1200/jco-25-00225
Published: 2025-09-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00225,
  title = {Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without
            <i>BRCA</i>
            Mutation},
  author = {Panagiotis A. Konstantinopoulos and Jae Weon Kim and Gilles Freyer and Jung Yun Lee and Lydia Gaba and Rachel N. Grisham and Nicoletta Colombo and Xiaohua Wu and Jalid Sehouli and Felipe Cruz and David Cibula and Bradley J. Monk and Gitte-Bettina Nyvang and Michael Friedlander and Domenica Lorusso and Els Van Nieuwenhuysen and Rozita Malik and Rosalind Glasspool and Christian Marth and Alexandra Leary and Alfonso Cortés-Salgado and Claudio Zamagni and Frederik Marmé and Jozef Sufliarsky and Patsy Hinson and Monica Zuradelli and Craig Wang and Fei Su and Ines Paule and Michelle Miller and Ursula A. Matulonis and Antonio González-Martín},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-00225},
  url = {https://doi.org/10.1200/jco-25-00225}
}

RIS

TY  - JOUR
TI  - Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without
            <i>BRCA</i>
            Mutation
AU  - Panagiotis A. Konstantinopoulos
AU  - Jae Weon Kim
AU  - Gilles Freyer
AU  - Jung Yun Lee
AU  - Lydia Gaba
AU  - Rachel N. Grisham
AU  - Nicoletta Colombo
AU  - Xiaohua Wu
AU  - Jalid Sehouli
AU  - Felipe Cruz
AU  - David Cibula
AU  - Bradley J. Monk
AU  - Gitte-Bettina Nyvang
AU  - Michael Friedlander
AU  - Domenica Lorusso
AU  - Els Van Nieuwenhuysen
AU  - Rozita Malik
AU  - Rosalind Glasspool
AU  - Christian Marth
AU  - Alexandra Leary
AU  - Alfonso Cortés-Salgado
AU  - Claudio Zamagni
AU  - Frederik Marmé
AU  - Jozef Sufliarsky
AU  - Patsy Hinson
AU  - Monica Zuradelli
AU  - Craig Wang
AU  - Fei Su
AU  - Ines Paule
AU  - Michelle Miller
AU  - Ursula A. Matulonis
AU  - Antonio González-Martín
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-00225
UR  - https://doi.org/10.1200/jco-25-00225
ER  -

APA

Konstantinopoulos, P. A., Kim, J. W., Freyer, G., Lee, J. Y., Gaba, L., Grisham, R. N., Colombo, N., Wu, X., Sehouli, J., Cruz, F., Cibula, D., Monk, B. J., Nyvang, G., Friedlander, M., Lorusso, D., Nieuwenhuysen, E. V., Malik, R., Glasspool, R., Marth, C., Leary, A., Cortés-Salgado, A., Zamagni, C., Marmé, F., Sufliarsky, J., Hinson, P., Zuradelli, M., Wang, C., Su, F., Paule, I., Miller, M., Matulonis, U. A., & González-Martín, A. (2025). Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00225

Source records

crossref · retrieved 2026-09-25T20:43:00.972Z